Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

0927GCC: Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery

This study has been terminated.
(low accrual)
Sponsor:
Collaborator:
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Katherine Tkaczuk, University of Maryland
ClinicalTrials.gov Identifier:
NCT01234532
First received: November 3, 2010
Last updated: March 1, 2016
Last verified: March 2016
  Purpose
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving entinostat together with anastrozole may be an effective treatment for breast cancer.

Condition Intervention Phase
Estrogen Receptor-negative Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Triple-negative Breast Cancer
Drug: entinostat
Drug: anastrozole
Other: diagnostic laboratory biomarker analysis
Procedure: therapeutic conventional surgery
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response

Resource links provided by NLM:


Further study details as provided by University of Maryland:

Primary Outcome Measures:
  • Recommended phase II dose of entinostat in combination with anastrozole (pilot) [ Time Frame: 29 days ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of entinostat in combination with anastrozole (pilot) [ Time Frame: Up to 30 days post treatment ] [ Designated as safety issue: Yes ]
    To address the safety of the regimen, a maximum width 90% confidence interval for any grade 3 or higher toxicity will be approximately 30%. For 35 patients in this study, if the true unknown probability of a rare toxicity is 10%, the probability of observing 1 or more toxicities is 97%, and if the true toxicity rate is 5% then the probability of observing one or more rare toxicities is 83%.

  • Change in proliferative index (Ki67) (phase II) [ Time Frame: Baseline to the time of surgery, within 6 days after the last dose of entinostat ] [ Designated as safety issue: No ]
    The 95% confidence intervals will be constructed for the observed proportions. Exploratory data analysis and appropriate graphs will be used to decide whether data transformation (e.g. log or square-root) is necessary to assure an approximate normality. All descriptive statistics will be reported for ER and Ki67 expression. The general linear model approach and/or its non parametric alternative, the Wilcoxon test, will be used to assess whether there is any evidence of changes due to treatment.

  • Change in Estrogen-receptor (ER) expression (phase II) [ Time Frame: Baseline to the time of surgery, within 6 days after the last dose of entinostat ] [ Designated as safety issue: No ]
    The 95% confidence intervals will be constructed for the observed proportions. Exploratory data analysis and appropriate graphs will be used to decide whether data transformation (e.g. log or square-root) is necessary to assure an approximate normality. All descriptive statistics will be reported for ER and Ki67 expression. The general linear model approach and/or its non parametric alternative, the Wilcoxon test, will be used to assess whether there is any evidence of changes due to treatment.


Secondary Outcome Measures:
  • Change in PR, HER2, EGFR, CK5/6, aromatase, tissue histone H3 and H4 acetylation [ Time Frame: Baseline to the time of surgery, within 6 days after the last dose of entinostat ] [ Designated as safety issue: No ]
    Will be treated as continuous variables. Multivariate analysis of variance may also be used to compare correlated biomarkers' expression. Correlation between biomarkers will be estimated and tested. The repeated measures model approach will be also used. Categorical outcome data (e.g., number of proteins expressed) will be recorded, proportions will be estimated and compared using the Fisher's exact test.

  • Response to entinostat and anastrozole [ Time Frame: Up to the time of surgery, within 6 days after the last dose of entinostat ] [ Designated as safety issue: No ]
    Clinical and pathological response rate with the corresponding 90% or 95% CI will be estimated for all eligible patients. The possible association between response rate and dose level will also be assessed.


Enrollment: 5
Study Start Date: October 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (entinostat, anastrozole, and surgery)

Patients receive entinostat PO once daily on days 1, 8, 15, 22, and 29 and anastrozole PO once daily on days 4-29. Patients then undergo mastectomy or lumpectomy.

Tumor tissue samples are collected at baseline or from original diagnosis, and during surgery for correlative studies by IHC and RT-PCR. Blood samples are also collected at baseline, on days 1 and 15, and during surgery for correlative studies.

Drug: entinostat
Given PO
Drug: anastrozole
Given PO
Other: diagnostic laboratory biomarker analysis
Correlative studies
Procedure: therapeutic conventional surgery
Undergo mastectomy or lumpectomy

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of entinostat in combination with anastrozole or tamoxifen. (Pilot) II. To determine the optimal dose of entinostat in combination with anastrozole or tamoxifen for phase II. (Pilot) III. To determine baseline and percentage change in proliferative index (Ki67) before and after treatment with entinostat and anastrozole/tamoxifen in triple negative breast cancer (TNBC). (Phase II) IV. To determine the estrogen receptor (ER) expression after treatment with entinostat and anastrozole/tamoxifen in TNBC. (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate baseline and change in the expression levels of progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6), and aromatase before and after treatment with entinostat and anastrozole/tamoxifen.

II. To assess baseline and change in tumor tissue histone H3 and H4 acetylation before and after treatment with entinostat and anastrozole/tamoxifen.

III. To assess the clinical and pathological response to preoperative combination of entinostat and anastrozole/tamoxifen in TNBC.

TERTIARY OBJECTIVES:

I. To correlate the levels of histone H3 and H4 acetylation in tumors with the changes in Ki67 and ER.

II. To evaluate baseline and change in gene methylation silencing and expression of candidate genes in tissues and in circulating DNA, including estrogen receptor (ER)-alpha, ER-beta, RAR-beta, cyclin D2, Twist, RASSF1A, and HIN-1.

III. To correlate entinostat trough concentrations with histone H3 and H4 acetylation in tumors as well as the change in Ki67 and ER.

IV. To evaluate baseline and change in the global gene expression profile before and after treatment with entinostat and anastrozole/tamoxifen.

OUTLINE: This is a multicenter, pilot study followed by a phase II study.

Patients receive entinostat orally (PO) once daily on days 1, 8, 15, 22, and 29 and anastrozole PO once daily on days 4-29. Patients then undergo mastectomy or lumpectomy.

Tumor tissue samples are collected at baseline or from original diagnosis, and during surgery for correlative studies by IHC and RT-PCR. Blood samples are also collected at baseline, on days 1 and 15, and during surgery for correlative studies.

After completion of study therapy, patients are followed up for 30 days.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Female greater than or equal to 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status <2 (see Appendix A).
  • Histologically confirmed adenocarcinoma of the breast.
  • Evidence of hormone insensitivity (ER and PR negative) of primary tumor tissue. ER negative is define as ER 0 or < 1% staining by immunohistochemistry. PR negativity is defined as PR < 1% staining by immunohistochemistry.
  • HER2 negative in the primary tumor tissue as defined by:

    • Immunohistochemistry (IHC) Grade 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within ≤10% of the invasive tumor cell
    • IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumor cell
    • IHC Grade 2+ staining intensity by means of IHC analysis with no gene amplification below.
    • No gene amplification on ISH based on

      • Single-probe average HER2 copy number <4.0 signals/cell
      • Dual-probe HER2/CEP17 ratio <2.0 with an average HER2 copy number <4.0 signals/cell
  • Ability to understand and the willingness to sign a written informed consent document.
  • Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy.
  • Women of childbearing potential must have negative (serum or urine) pregnancy test within 7 days prior to registration.
  • Patients must have adequate tumor tissue sample prior to the enrolment available for correlative studies as defined below:

    • Core needle biopsy or incisional biopsy samples that can provide ≥ 3 unstained sections of 5 micron thickness. Fine needle aspiration (FNA) sample alone is not sufficient except in the second cohort.
    • Additional core needle biopsy needs to be performed in the patients who agree to participate in this study and do not have adequate tumor tissue sample.
  • Patients must have adequate organ and marrow function as defined below:

    • Hemoglobin ≥ 9.0 g/dL
    • Leukocytes >2,500/mcL
    • Absolute neutrophil count >1,100/mcL
    • Platelets >100,000/mcL
    • Total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) <2.5 x institutional upper limit of normal
    • Creatinine within normal institutional limits or creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal

Additional Inclusion Criteria for the First cohort:

- Unresected operable breast cancer that meets the following clinical stages (see Appendix B):

  • T1b, T1c, or T2
  • N0 or N1
  • M0 (No distant metastasis)

Additional Inclusion Criteria for the Second cohort:

  • Unresectable, inoperable, recurrent local-regional breast cancer or
  • Metastatic (stage IV) breast cancer
  • Patients must have measurable or evaluable disease (i.e. ascites or pleural/pericardial effusion). Patients with bone metastatic only will be excluded.
  • Patients must not have rapidly progressive disease, extensive visceral involvement, or any high risk characteristics that are not appropriate for this treatment as per investigator's discretion.
  • Patients must receive at least one prior line of chemotherapy but not more 2 prior chemotherapy regimens for stage IV breast cancer. Prior chemotherapy in the adjuvant and /or neoadjuvant setting is permitted. However, patients must have finished chemotherapy at least 2 weeks prior to enrollment.
  • Patients must have an accessible tumor lesion from which a fine needle aspirate or preferably a core biopsy specimen can be obtained. Patients with FNA only samples are allowed in this cohort. Ascites or pleural/pericardial effusion alone is not sufficient.
  • Patients must be willing to provide consents for 2 research biopsies. However, the pretreatment biopsy can be omitted in patients who have recent biopsy but have not been started on breast cancer treatment within 12 weeks prior to the registration and there is adequate tumor tissue sample

Exclusion Criteria

  • Patients may not be receiving any other investigational agents.
  • Prior exposure to other HDAC inhibitors. However, prior valproic acid exposure is allowed providing

    ≥ 30 days wash-out period.

  • History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to entinostat, benzamide, anastrozole, or tamoxifen.
  • Any medical condition which in the opinion of the investigator puts the patient at risk of potentially serious complications while on this therapy. Examples: HIV, unstable angina, uncontrolled heart failure or hypertension, uncontrolled hyperlipidemia, uncontrolled diabetes mellitus, uncontrolled systemic infection.
  • Previous or current systemic malignancy within the past 3 years other than breast cancer or adequately treated cervical carcinoma in situ or basal/squamous carcinoma of the skin.

Inclusion of Minorities

- Women of all races and ethnic groups are eligible for this trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01234532

Locations
United States, Maryland
University of Maryland Baltimore
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
University of Maryland
Syndax Pharmaceuticals
Investigators
Principal Investigator: Saranya Chumsri University of Chicago Comprehensive Cancer Center
  More Information

Responsible Party: Katherine Tkaczuk, Professor of Medicine, University of Maryland
ClinicalTrials.gov Identifier: NCT01234532     History of Changes
Other Study ID Numbers: HP-00047658  NCI-2011-02542  CDR0000687507  8597 
Study First Received: November 3, 2010
Last Updated: March 1, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Anastrozole
Entinostat
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Histone Deacetylase Inhibitors

ClinicalTrials.gov processed this record on September 23, 2016